mechlorethamine has been researched along with Glial Cell Tumors in 14 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma." | 9.08 | Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. ( Buckner, JC; Burch, PA; Dinapoli, RP; Galanis, E; Mailliard, JA; Morton, RF; Novotny, PJ; Rowland, KM; Schaefer, PL; Scheithauer, BW; Vukov, AM, 1998) |
| "We undertook a phase II study of combination chemotherapy with mechlorethamine (nitrogen mustard) 6 mg/m2 intravenously day 1 and day 8, vincristine 2 mg intravenously day 1 and day 8, and procarbazine 100 mg/m2 orally days 1 through 14 (MOP) in adults with recurrent high-grade glioma." | 9.06 | Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. ( Baptista, J; Clark, K; Coyle, T; Graziano, S; King, R; Kirshner, J; Newman-Palmer, N; Poiesz, B; Scalzo, A; Winfield, J, 1990) |
| "The authors report the clinical features of hypersensitivity reactions believed to result from procarbazine in eight patients treated with mechlorethamine, vincristine, and procarbazine (MOP) for high-grade glioma." | 8.78 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. ( Bushunow, P; Coyle, T; Graziano, S; Winfield, J; Wright, J, 1992) |
| "Biopsy samples and cultured cells derived from them were obtained from 39 patients with malignant glioma and were analyzed for 1) glutathione (GSH) content; 2) sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and/or nitrogen mustard (HN2) treatment and 3) the effect of buthionine sulfoximine (BSO) treatment on BCNU and/or HN2 cytotoxicity." | 7.68 | Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. ( Allalunis-Turner, MJ; Allen, PB; Aronyk, KE; Day, RS; Fulton, DS; Huyser-Wierenga, D; McKean, JD; Petruk, KC; Urtasun, RC; Weir, BK, 1991) |
| "Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma." | 5.08 | Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. ( Buckner, JC; Burch, PA; Dinapoli, RP; Galanis, E; Mailliard, JA; Morton, RF; Novotny, PJ; Rowland, KM; Schaefer, PL; Scheithauer, BW; Vukov, AM, 1998) |
| "We undertook a phase II study of combination chemotherapy with mechlorethamine (nitrogen mustard) 6 mg/m2 intravenously day 1 and day 8, vincristine 2 mg intravenously day 1 and day 8, and procarbazine 100 mg/m2 orally days 1 through 14 (MOP) in adults with recurrent high-grade glioma." | 5.06 | Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. ( Baptista, J; Clark, K; Coyle, T; Graziano, S; King, R; Kirshner, J; Newman-Palmer, N; Poiesz, B; Scalzo, A; Winfield, J, 1990) |
| "The authors report the clinical features of hypersensitivity reactions believed to result from procarbazine in eight patients treated with mechlorethamine, vincristine, and procarbazine (MOP) for high-grade glioma." | 4.78 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. ( Bushunow, P; Coyle, T; Graziano, S; Winfield, J; Wright, J, 1992) |
| "Estramustine phosphate (EMP) is an anti-microtubule agent that induces apoptosis of glioma cells." | 3.71 | Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2. ( Noha, M; Sugisaki, Y; Takahashi, H; Teramoto, A; Watanabe, K; Yoshida, D, 2001) |
| "Biopsy samples and cultured cells derived from them were obtained from 39 patients with malignant glioma and were analyzed for 1) glutathione (GSH) content; 2) sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and/or nitrogen mustard (HN2) treatment and 3) the effect of buthionine sulfoximine (BSO) treatment on BCNU and/or HN2 cytotoxicity." | 3.68 | Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. ( Allalunis-Turner, MJ; Allen, PB; Aronyk, KE; Day, RS; Fulton, DS; Huyser-Wierenga, D; McKean, JD; Petruk, KC; Urtasun, RC; Weir, BK, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (64.29) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| HATIBOGLU, I | 1 |
| OWENS, G | 2 |
| JAVID, R | 1 |
| TALLON, M | 1 |
| STEPANIAN, G | 1 |
| BELMUSTO, L | 1 |
| Galanis, E | 1 |
| Buckner, JC | 1 |
| Burch, PA | 1 |
| Schaefer, PL | 1 |
| Dinapoli, RP | 1 |
| Novotny, PJ | 1 |
| Scheithauer, BW | 1 |
| Rowland, KM | 1 |
| Vukov, AM | 1 |
| Mailliard, JA | 1 |
| Morton, RF | 1 |
| Yoshida, D | 1 |
| Noha, M | 1 |
| Watanabe, K | 1 |
| Takahashi, H | 1 |
| Sugisaki, Y | 1 |
| Teramoto, A | 1 |
| Coyle, T | 2 |
| Bushunow, P | 1 |
| Winfield, J | 2 |
| Wright, J | 1 |
| Graziano, S | 2 |
| Allalunis-Turner, MJ | 1 |
| Day, RS | 1 |
| McKean, JD | 1 |
| Petruk, KC | 1 |
| Allen, PB | 1 |
| Aronyk, KE | 1 |
| Weir, BK | 1 |
| Huyser-Wierenga, D | 1 |
| Fulton, DS | 1 |
| Urtasun, RC | 1 |
| Baptista, J | 1 |
| Clark, K | 1 |
| Poiesz, B | 1 |
| Kirshner, J | 1 |
| Scalzo, A | 1 |
| Newman-Palmer, N | 1 |
| King, R | 1 |
| Evans, CG | 1 |
| Bodell, WJ | 3 |
| Tokuda, K | 1 |
| Doane-Setzer, P | 1 |
| Smith, MT | 1 |
| Takaue, Y | 1 |
| Sullivan, MP | 1 |
| Ramirez, I | 1 |
| Cleary, KR | 1 |
| van Eys, J | 2 |
| Baram, TZ | 1 |
| Cangir, A | 1 |
| Bruner, JM | 1 |
| Martinez-Prieto, J | 1 |
| Aida, T | 2 |
| Brdar, B | 1 |
| Mahaley, MS | 1 |
| Woodhall, B | 1 |
1 review available for mechlorethamine and Glial Cell Tumors
| Article | Year |
|---|---|
Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Hypersensit | 1992 |
2 trials available for mechlorethamine and Glial Cell Tumors
| Article | Year |
|---|---|
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Female; Glioma; | 1998 |
Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; G | 1990 |
11 other studies available for mechlorethamine and Glial Cell Tumors
| Article | Year |
|---|---|
Results of intermittent, prolonged infusion of nitrogen mustard into the carotid artery in twelve patients with cerebral gliomas.
Topics: Brain Neoplasms; Carotid Arteries; Glioma; Humans; Mechlorethamine; Nitrogen Mustard Compounds | 1961 |
ARTERIAL INFUSION CHEMOTHERAPY OF PRIMARY GLIOMAS.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Glioma; Mechloreth | 1963 |
Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Astrocytes; Brain Neoplasms; Ele | 2001 |
Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Buthionine Sulfoximine; C | 1991 |
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp | 1987 |
Second malignant neoplasm in treated Hodgkin's disease. Report of a patient and scope of the problem.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Combined Modality Therapy; G | 1986 |
Salvage chemotherapy for recurrent primary brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chi | 1988 |
Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
Topics: Carmustine; Cell Line; Cell Survival; Cisplatin; DNA; Dose-Response Relationship, Drug; Drug Resista | 1987 |
[Anticancer drug induced sister chromatid exchange and correlation to cell survival in human brain tumor cells].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cisplatin; Glioma; Hum | 1987 |
Induction of plasminogen activator by alkylating agents in a repair defective human glioblastoma cell strain.
Topics: Alkylating Agents; Cell Line; Cycloheximide; DNA Repair; Enzyme Induction; Glioma; Humans; Mechloret | 1986 |
Regional chemotherapeutic perfusion and infusion of brain and face tumors.
Topics: Adenocarcinoma; Ameloblastoma; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carcinoma; Carci | 1967 |